JP2005537809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005537809A5 JP2005537809A5 JP2004535633A JP2004535633A JP2005537809A5 JP 2005537809 A5 JP2005537809 A5 JP 2005537809A5 JP 2004535633 A JP2004535633 A JP 2004535633A JP 2004535633 A JP2004535633 A JP 2004535633A JP 2005537809 A5 JP2005537809 A5 JP 2005537809A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- heavy chain
- nucleic acid
- cleavage site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 52
- 229920001184 polypeptide Polymers 0.000 claims 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims 50
- 238000003776 cleavage reaction Methods 0.000 claims 13
- 150000007523 nucleic acids Chemical group 0.000 claims 13
- 230000007017 scission Effects 0.000 claims 13
- 108010013369 Enteropeptidase Proteins 0.000 claims 10
- 102100029727 Enteropeptidase Human genes 0.000 claims 10
- 108010055044 Tetanus Toxin Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 238000000746 purification Methods 0.000 claims 6
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 241000193155 Clostridium botulinum Species 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 3
- 241000193403 Clostridium Species 0.000 claims 3
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 102000006240 membrane receptors Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000006337 proteolytic cleavage Effects 0.000 claims 3
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 101710138657 Neurotoxin Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 229940094657 botulinum toxin type a Drugs 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 231100001102 clostridial toxin Toxicity 0.000 claims 2
- 230000028023 exocytosis Effects 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 101000879393 Aplysia californica Synaptobrevin Proteins 0.000 claims 1
- 108030001720 Bontoxilysin Proteins 0.000 claims 1
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 claims 1
- 108010059378 Endopeptidases Proteins 0.000 claims 1
- 102000005593 Endopeptidases Human genes 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims 1
- 108010005730 R-SNARE Proteins Proteins 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims 1
- 102000002215 Synaptobrevin Human genes 0.000 claims 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 claims 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 claims 1
- 102000050389 Syntaxin Human genes 0.000 claims 1
- 108030001722 Tentoxilysin Proteins 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000003499 nucleic acid array Methods 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/241,596 US7192596B2 (en) | 1996-08-23 | 2002-09-12 | Recombinant toxin fragments |
| PCT/GB2003/003824 WO2004024909A2 (en) | 2002-09-12 | 2003-09-12 | Recombinant colstridium neurotoxin fragments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010229133A Division JP5570936B2 (ja) | 2002-09-12 | 2010-10-08 | 組換え毒素フラグメント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005537809A JP2005537809A (ja) | 2005-12-15 |
| JP2005537809A5 true JP2005537809A5 (enExample) | 2008-07-17 |
Family
ID=31991213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004535633A Pending JP2005537809A (ja) | 2002-09-12 | 2003-09-12 | 組換え毒素フラグメント |
| JP2010229133A Expired - Fee Related JP5570936B2 (ja) | 2002-09-12 | 2010-10-08 | 組換え毒素フラグメント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010229133A Expired - Fee Related JP5570936B2 (ja) | 2002-09-12 | 2010-10-08 | 組換え毒素フラグメント |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7192596B2 (enExample) |
| EP (2) | EP1537207A2 (enExample) |
| JP (2) | JP2005537809A (enExample) |
| AU (1) | AU2003267559B2 (enExample) |
| CA (1) | CA2498502C (enExample) |
| WO (1) | WO2004024909A2 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060141572A1 (en) * | 1993-09-21 | 2006-06-29 | Smith Leonard A | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB9824282D0 (en) * | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| CA2380457A1 (en) | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
| US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| US7368532B2 (en) * | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| WO2001058936A2 (en) * | 1999-12-02 | 2001-08-16 | Microbiological Research Authority | Constructs for delivery of therapeutic agents to neuronal cells |
| US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
| WO2002036758A2 (en) * | 2000-11-06 | 2002-05-10 | United States Army Medical Research And Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| WO2006026780A1 (en) * | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
| CA2588758C (en) * | 2004-11-22 | 2017-01-03 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| CA2588292C (en) * | 2004-12-01 | 2019-01-15 | Health Protection Agency | Non-cytotoxic protein conjugates |
| DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| WO2007094754A2 (en) * | 2005-01-27 | 2007-08-23 | The Regents Of The University Of Califordnia | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| CA2601592A1 (en) * | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| DK1926744T4 (en) * | 2005-09-19 | 2019-01-28 | Allergan Inc | CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES |
| WO2007106115A1 (en) * | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| US20080118532A1 (en) * | 2006-06-01 | 2008-05-22 | Atassi M Zouhair | Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides |
| AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| EP2038299A2 (en) | 2006-07-11 | 2009-03-25 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| WO2008008803A2 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| CA2680741A1 (en) * | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| EP2167119B1 (en) | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
| GB2456549A (en) * | 2008-01-18 | 2009-07-22 | Health Prot Agency | Modified botulinum neurotoxin serotype E (BoNT/E) peptides |
| RU2010120016A (ru) * | 2007-10-23 | 2011-11-27 | Аллерган, Инк. (Us) | Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов |
| US9000131B2 (en) * | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| EP2528941A4 (en) * | 2010-01-25 | 2013-05-29 | Univ New York | FOR TRANSPORT STUDIES AND NEURONAL ADMINISTRATION, MANIPULATED RECOMBINANT DERIVATIVES FROM BOTULINUM NEUROTOXINES |
| AU2011288456B2 (en) * | 2010-08-11 | 2015-04-16 | Merz Pharma Gmbh & Co. Kgaa | Selective manufacture of recombinant neurotoxin polypeptides |
| WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| US20130330369A1 (en) | 2010-10-08 | 2013-12-12 | Allergan, Inc. | Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| US20140287433A1 (en) * | 2011-07-19 | 2014-09-25 | ETH Zürich | Means and methods for determining clostridial neurotoxins |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| JP2015527067A (ja) * | 2012-08-20 | 2015-09-17 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アウフ アクティーン | Ｎ末端リシンを包有する組換タンパク質を製造する新規の方法 |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| US9315549B2 (en) | 2013-01-28 | 2016-04-19 | New York University | Treatment methods using atoxic neurotoxin derivatives |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| EP3156412B1 (en) * | 2014-05-29 | 2020-01-08 | Procell Therapeutics Inc. | Novel cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| EP3230457B1 (en) | 2014-12-09 | 2021-06-30 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
| DK3242884T3 (da) | 2015-01-09 | 2021-04-19 | Ipsen Bioinnovation Ltd | Kationiske neurotoksiner |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| JP7118055B2 (ja) * | 2016-09-29 | 2022-08-15 | イプセン バイオファーム リミテッド | ハイブリッド神経毒 |
| US20210187194A1 (en) | 2018-02-26 | 2021-06-24 | Ipsen Biopharm Limited | Use of Ultrasound to Guide Injection of Non-cytotoxic Protease |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| KR102192192B1 (ko) * | 2019-12-06 | 2020-12-17 | 주식회사 칸젠 | 보툴리눔 독소 및 세포 투과성 펩타이드를 포함하는 재조합 단백질과 이를 포함하는 화장료 조성물 |
| KR102610179B1 (ko) * | 2019-12-18 | 2023-12-05 | 엠브릭스 주식회사 | 보툴리눔 신경 독소의 안전한 제조 방법 |
| US12023400B2 (en) | 2020-08-07 | 2024-07-02 | Kan Zen Co., Ltd | Recombinant proteins comprising botulinum toxin and cell penetrating peptide and cosmetic composition comprising thereof |
| WO2022046768A1 (en) * | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Botulinum neurotoxin proteins and methods to engineer and generate same |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| BR112023020057A2 (pt) | 2021-03-30 | 2024-03-12 | Ipsen Biopharm Ltd | Tratamento de dor e distúrbios inflamatórios |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| WO2024098029A2 (en) * | 2022-11-04 | 2024-05-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of measuring absolute length of individual telomeres |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| CN118006523B (zh) * | 2024-01-17 | 2025-03-11 | 河北封章生物科技有限公司 | A型肉毒素的重组基因工程菌及其制备和应用 |
| CN118812658A (zh) * | 2024-04-26 | 2024-10-22 | 北京化工大学 | 一种开关式穿膜肽重组去皱蛋白组合套装及其应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880911A (en) * | 1982-03-19 | 1989-11-14 | G. D. Searle & Co. | Fused polypeptides and methods for their detection |
| US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| US5474911A (en) * | 1989-12-01 | 1995-12-12 | The Board Of Trustees Of Leland Stanford Jr. University | Promotion of high specificity molecular assembly |
| AU657087B2 (en) | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
| AU1582692A (en) | 1991-03-08 | 1992-10-06 | Protein Design Labs, Inc. | Recombinant double chain immunotoxins |
| WO1993004191A1 (en) | 1991-08-15 | 1993-03-04 | Neorx Corporation | Noncytolytic toxin conjugates |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9305919D0 (en) | 1993-03-22 | 1993-05-12 | Health Lab Service Board | Botulinum toxin polypeptides and their use as vaccines |
| US5563823A (en) * | 1993-08-31 | 1996-10-08 | Macronix International Co., Ltd. | Fast FLASH EPROM programming and pre-programming circuit design |
| US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US5962637A (en) * | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| DE69535530D1 (de) | 1994-10-24 | 2007-08-16 | Ophidian Pharm Inc | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| JP4229341B2 (ja) * | 1996-03-23 | 2009-02-25 | 財団法人阪大微生物病研究会 | 破傷風毒素の機能的フラグメント抗原及び破傷風ワクチン |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| EP1105153A4 (en) | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
| GB9618960D0 (en) * | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
| US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| US6444209B1 (en) * | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US6822076B2 (en) * | 1998-05-13 | 2004-11-23 | Biotecon Therapeutics Gmbh | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| EP1105508B1 (en) * | 1998-08-17 | 2002-09-04 | Europäisches Laboratorium Für Molekularbiologie (Embl) | Method for purifying biomolecule or protein complexes |
| US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| US20080249019A1 (en) | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
| JP4749548B2 (ja) * | 1998-09-30 | 2011-08-17 | ニユー・イングランド・バイオレイブズ・インコーポレイテツド | インテイン媒介ペプチド連結 |
| GB9824282D0 (en) | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| GB9907429D0 (en) * | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| CA2377513A1 (en) * | 1999-06-25 | 2001-01-04 | Universitat Zurich | Hetero-associating coiled-coil peptides |
| GB9914861D0 (en) | 1999-06-25 | 1999-08-25 | Imperial College | Tetanus toxin polypeptides |
| WO2001001137A1 (en) * | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
| JP2003505020A (ja) * | 1999-07-02 | 2003-02-12 | ジェネンテック・インコーポレーテッド | ペプチドリガンドドメイン及び多量体化ドメインを含む融合ペプチド |
| US6535580B1 (en) * | 1999-07-27 | 2003-03-18 | Agere Systems Inc. | Signature device for home phoneline network devices |
| EP1074563A1 (en) * | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| CA2380457A1 (en) * | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
| US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| GB9921592D0 (en) | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
| US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| US7368532B2 (en) * | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| WO2001058936A2 (en) * | 1999-12-02 | 2001-08-16 | Microbiological Research Authority | Constructs for delivery of therapeutic agents to neuronal cells |
| US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
| GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
| GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| US7364586B2 (en) * | 2001-12-21 | 2008-04-29 | The Trustees Of Columbia University In The City Of New York | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis |
| AU2003237346A1 (en) | 2002-05-31 | 2003-12-19 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| GB0216865D0 (en) | 2002-07-19 | 2002-08-28 | Microbiological Res Authority | Targetted agents for nerve regeneration |
| GB0311961D0 (en) | 2003-05-23 | 2003-06-25 | Health Prot Agency | Mass-based toxin assay and substrates therefor |
| EP1651666B1 (en) * | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| PT1729821E (pt) * | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
| US7811584B2 (en) | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| WO2006026780A1 (en) | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
| US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| CA2588758C (en) * | 2004-11-22 | 2017-01-03 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| CA2595115C (en) | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| US7659092B2 (en) | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| CA2588292C (en) | 2004-12-01 | 2019-01-15 | Health Protection Agency | Non-cytotoxic protein conjugates |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| CA2601592A1 (en) | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| GB0610868D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| EP2038299A2 (en) | 2006-07-11 | 2009-03-25 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
-
2002
- 2002-09-12 US US10/241,596 patent/US7192596B2/en not_active Expired - Fee Related
-
2003
- 2003-09-12 CA CA2498502A patent/CA2498502C/en not_active Expired - Fee Related
- 2003-09-12 US US10/527,411 patent/US20060110410A1/en not_active Abandoned
- 2003-09-12 EP EP03748251A patent/EP1537207A2/en not_active Withdrawn
- 2003-09-12 WO PCT/GB2003/003824 patent/WO2004024909A2/en not_active Ceased
- 2003-09-12 AU AU2003267559A patent/AU2003267559B2/en not_active Ceased
- 2003-09-12 JP JP2004535633A patent/JP2005537809A/ja active Pending
- 2003-09-12 EP EP20100166552 patent/EP2280066A3/en not_active Withdrawn
-
2010
- 2010-10-07 US US12/900,214 patent/US9006395B2/en not_active Expired - Fee Related
- 2010-10-08 JP JP2010229133A patent/JP5570936B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005537809A5 (enExample) | ||
| CA2264191A1 (en) | Recombinant toxin fragments | |
| Walker et al. | Efficient and rapid affinity purification of proteins using recombinant fusion proteases | |
| JP5570936B2 (ja) | 組換え毒素フラグメント | |
| Yamasaki et al. | Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. | |
| WEIL et al. | Biosynthesis of the lantibiotic Pep5: isolation and characterization of a prepeptide containing dehydroamino acids | |
| Kanai et al. | Poly (U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase | |
| JP2004532033A5 (enExample) | ||
| WO2006076902A3 (de) | Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form | |
| ATE421977T1 (de) | Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie | |
| Forsberg et al. | An evaluation of different enzymatic cleavage methods for recombinant fusion proteins, applied on des (1–3) insulin-like growth factor I | |
| US7094548B2 (en) | Purification of recombinant proteins fused to multiple epitopes | |
| KR870001311A (ko) | 단백질 및 폴리펩티드의 제조 방법 | |
| AU1503697A (en) | Method for cleaving chimeric protein using processing enzyme | |
| Shimokata et al. | Substrate recognition by mitochondrial processing peptidase toward the malate dehydrogenase precursor | |
| Kwon et al. | Structural domains of IS10 transposase and reconstitution of transposition activity from proteolytic fragments lacking an interdomain linker. | |
| JP4273250B6 (ja) | 組換え毒素フラグメント | |
| US7189540B2 (en) | Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proteins | |
| Plastino et al. | Limited proteolysis of Hansenula polymorpha yeast amine oxidase: isolation of a C-terminal fragment containing both a copper and quino-cofactor | |
| Kluh et al. | Proteases of HIV-1 and MAV Hydrolyze Specifically Human Apo-Hemopexin | |
| JP2006320220A (ja) | プロテインａ融合ポリペプチドの製造に利用するｄｎａ配列、組換え発現ベクター、形質転換体、およびその融合ポリペプチドの製造方法 | |
| HK1152966A (en) | Recombinant clostridium neurotoxin fragments |